Absci Corporation Presents at Jefferies London Healthcare Conference 2025 Transcript

Absci Corporation presented at the Jefferies London Healthcare Conference 2025, highlighting its focus on using AI to tackle undruggable targets in drug discovery. The company's CEO, Sean McClain, discussed the translation of AI drug discovery into clinical success, citing 2 Phase II readouts for its assets ABS-201 in AGA and endometriosis within the next 24 months. McClain emphasized the importance of a multilingual team and a data flywheel to leverage AI technology for disease treatment.